2020 Innovation-Based Optimism for Lung Cancer Outcomes

Lung cancer is the leading cause of cancer death in both males and females in the U.S. and worldwide. Owing to advances in prevention, screening/early detection, and therapy, lung cancer mortality rates are decreasing and survival rates are increasing. These innovations are based on scientific discoveries in imaging, diagnostics, genomics, molecular therapy, and immunotherapy. Outcomes have improved in all histologies and stages. This review provides information on the clinical implications of these innovations that are practical for the practicing physicians, especially oncologists of all specialities who diagnose and treat patients with lung cancer. Implications for Practice Lung cancer survival rates have improved because of new prevention, screening, and therapy methods. This work provides a review of current standards for each of these areas including targeted and immunotherapies. Treatment recommendations are provided for all stages of lung cancer.

Automated summary

Lung cancer survival rates have improved due to new prevention, screening, and therapy methods. This review provides an overview of current standards in each area, including targeted and immunotherapies, and offers treatment recommendations for all stages of lung cancer.